Antivirals Aid HBeAg-Negative Chronic Hepatitis B Patients
By Lori Solomon HealthDay Reporter
WEDNESDAY, Jan. 3, 2024 -- Continuous nucleos(t)ide analog treatment is effective in lowering the risk for liver cirrhosis in hepatitis B e antigen (HBeAg)-negative chronic hepatitis B patients, according to a study published in the December issue of the Journal of Clinical and Translational Hepatology.
Jing Zhou, from Sichuan University in Chengdu, China, and colleagues analyzed 194 HBeAg-negative patients with normal alanine transaminase and positive hepatitis B virus (HBV) DNA (≥20 IU/mL) who were untreated, continued treatment, and discontinued treatment (67, 87, and 40 patients, respectively).
The researchers found that during a median follow-up of 54 months, the treatment-continued group achieved 100 percent virological response and significantly reduced aspartate aminotransferase-to-platelet ratio index and fibrosis-4 index scores. Compared with the untreated group, the risk for liver nodules and cirrhosis in the treatment-continued group was reduced. Results were similar compared with the treatment-discontinued group. Among patients with HBV DNA ≥2,000 IU/mL, adherence to treatment lowered the risks for liver cirrhosis compared with both the untreated and the treatment-discontinued groups. Hepatocellular carcinoma was reported by one patient in each of the untreated and treatment-discontinued groups, but not in the treatment-continued group.
"The indications of antiviral therapy should be expanded in that population, especially for those with HBV DNA levels ≥2,000 IU/mL," the authors write. "After treatment is initiated, patient medication compliance needs to be monitored continuously."
Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.
© 2024 HealthDay. All rights reserved.
Posted January 2024
Read this next
Chronic Hepatitis B Virus Is Undertreated
FRIDAY, May 3, 2024 -- Underassessment and undertreatment of chronic hepatitis B virus (HBV) is seen globally, according to a study published online May 1 in the Journal of...
Prevalence of Hepatitis Delta High in Hepatitis B Surface Antigen Chronic Carriers
THURSDAY, April 4, 2024 -- The prevalence of hepatitis delta virus (HDV) is high in hepatitis B surface antigen (HBs Ag) chronic carriers detected through annual screenings...
Missed, Undiagnosed Cirrhosis May Be Risk Factor for Cognitive Decline
FRIDAY, Feb. 2, 2024 -- Missed or undiagnosed cirrhosis may be a risk factor for cognitive decline, according to a study published online Jan. 31 in JAMA Network Open. Jasmohan...
More news resources
- FDA Medwatch Drug Alerts
- Daily MedNews
- News for Health Professionals
- New Drug Approvals
- New Drug Applications
- Drug Shortages
- Clinical Trial Results
- Generic Drug Approvals
Subscribe to our newsletter
Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.